• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·4142.TW
Share

Adimmune Corporation Stocks

NT$ 18.15Last Updated 30.09.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

NT$ 238.04M

NT$ 18.15
Key Takeaways

Risk factor

Limited trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Adimmune Corporation, a Taiwanese pharmaceutical company, specializes in the production and distribution of human vaccines. Its comprehensive product portfolio includes a range of critical immunizations. Key offerings feature the quadrivalent influenza vaccine, AdimFlu-S, alongside trivalent influenza vaccines and the Influenza A (H1N1) Virus Monovalent Vaccine. The company also provides tetanus toxoid products, vital for post-injury tetanus prevention, and Japanese encephalitis vaccines. Furthermore, Adimmune supplies purified Tuberculin and extends its expertise through contract manufacturing services. Established in 1965, the company initially operated under the name Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. It subsequently rebranded as Adimmune Corporation in 2001 and maintains its headquarters in Taichung, Taiwan.

Company Valuation

Slightly overvalued
3/7

Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 4142.TW is 21.0 and suggests 16% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.09.2026 13:51

DeepSeek has released tools for Huawei chips that could replace Nvidia's solutions

30.09.2026 13:04

The "Copper" Rally: Three Small-Cap Stocks Outperform a Sector Fund. What Will Drive Their Growth?

30.09.2026 12:01

The dollar has come close to its best performance in a month since June. What does the Fed's interest rate have to do with this?

30.09.2026 11:29

AI for Everyone: Robinhood Will Let Retail Investors Let Bots Trade Stocks on Their Behalf

30.09.2026 10:23

Top Stories This Morning: OpenAI Is Seeking $30 Billion; Trump Agrees on Industry Rules With AI Leaders

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026